PMGC Inc. (ELAB)
NasdaqCM: ELAB
· Real-Time Price · USD
5.31
-0.52 (-8.92%)
At close: Aug 28, 2026, 3:59 PM
5.42
+2.07%
After-hours: 7:48 PM
The price, the headline numbers and the latest news, in one place.
PMGC Inc. (ELAB) Stock Price, Analysis & Data
-8.92% (1D)
| Bid | 4.71 |
| Market Cap | 4.3M |
| Revenue (ttm) | 2.58M |
| Net Income (ttm) | -13.57M |
| -0.25 | |
| -1686.49 | |
| n/a | |
| n/a | |
| P/B (ttm) | 0.20 |
| P/S (ttm) | 1.67 |
| Earnings Date | n/a |
| Ask | 6.41 |
| Volume | 63,843 |
| Avg. Volume (20D) | 277,692 |
| Open | 5.87 |
| Previous Close | 5.83 |
| Day's Range | 5.24 - 5.97 |
| 52-Week Range | 5.24 - 2671.20 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ELAB
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss tre...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 21, 2023
Employees 32
Stock Exchange NasdaqCM
Ticker Symbol ELAB
Website https://pmgcholdings.com
Financial Performance
In 2025, PMGC's revenue was 590.08K, an increase of undefined% compared to the previous year's 0. Earnings were -7.75M, an increase of 24.05%.
Financial Statements
